Effectiveness of first line treatment with bortezomib prior to autologous stem cell transplantation for multiple myeloma
Abstract
Background: In this retrospective study we evaluated effectiveness and safety of first- line treatment with bortezomib and dexamethasone in multiple myeloma patients, comparing our results with already published clinical studies. Methods: Patients received bortezomib as part of everyday clinical practice and according to the latest guidelines of the Združenje hematologov Slovenije . Patients who were previously treated with first-line VAD (vincristine, doxorubicin modified with farmarubicine, dexamethasone), but due to uneffectiveness changed the treatment to bortezomib, were also included in the study. In 30 patients effectiveness was evaluated after average 3–4 cycles of bortezomib and dexamethasone according to the modified Southwest Oncology Group criteria. Treatment effectiveness was evaluated according to the previous VAD treatment, renal function and cytogenetic analysis. Side effects and reasons for early treatment discontinuation were described. Results: Patients received 2 to 8 cycles (median 4 cycles) of bortezomib and dexamethasone treatment. After average 3–4 cycles, 80 % of patients acheived good treatment response (56.7 % very good partial response, 23.3 % partial response). We observed that the treatment effectiveness was not influenced by previous VAD treatment, renal insufficiency and negative cytogenetic analisys, since we observed similar rates of very good partial response and partial response in patients without previous VAD treatment (82.3 % vs. 76.9 %), normal renal function (85.7 % vs. 75 % ) and normal cytogenetics (77.8 % vs. 80 %), although statistical evaluation was not possible due to small number of patients. The most common side effect was neuropathy (40 %) and in 5 patients (16.6 %), due to grade 3 or more, the treatment was discontinued. Other side effects were: anemia (26.6 %), infection (166 %), thrombocytopenia (10 %), neutropenia (6.6 %), gastrointestinal problems (23.3 %) and herpes zooster (6.6 %). Conclusions: Bortezomib (Velcade) in combination with dexamethasone is an effective and safe first-line multiple myeloma treatment and is not influenced by renal insuficience, unfavourable cytogenetic analysis or previous uneffective VAD treatment.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.